Your browser doesn't support javascript.
loading
Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You, Benoit; Salles, Gilles; Bachy, Emmanuel; Casasnovas, Olivier; Tilly, Hervé; Ribrag, Vincent; Sebban, Catherine; Hénin, Emilie; Guitton, Jéome; Tod, Michel; Freyer, Gilles.
Afiliação
  • You B; EMR UCBL/HCL 3738, Faculté de médecine Lyon Sud, Université Lyon 1, Lyon, France. benoit.you@chu-lyon.fr.
  • Salles G; Service d'Oncologie Médicale, Centre d'Investigation de Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL), Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Chemin du Grand Revoyet, 69495, Pierre-Benite, France. benoit.you@chu-lyon.fr.
  • Bachy E; Service d'hématologie, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Centre Hospitalier Lyon-Sud, Pierre-Benite, France.
  • Casasnovas O; Université Lyon 1, Lyon, France.
  • Tilly H; Service d'hématologie, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Centre Hospitalier Lyon-Sud, Pierre-Benite, France.
  • Ribrag V; Université Lyon 1, Lyon, France.
  • Sebban C; Service d'hématologie, Centre d'Investigation de Thérapeutiques en Oncologie et Hématologie de Lyon (CITOHL), Centre Hospitalier Universitaire de Dijon, 21034, Dijon, France.
  • Hénin E; Centre Henri Becquerel, 76038, Rouen, France.
  • Guitton J; Institut Gustave Roussy, 94805, Villejuif, France.
  • Tod M; Centre Léon Bérard, 69008, Lyon, France.
  • Freyer G; EMR UCBL/HCL 3738, Faculté de médecine Lyon Sud, Université Lyon 1, Lyon, France.
Cancer Chemother Pharmacol ; 76(5): 939-48, 2015 Nov.
Article em En | MEDLINE | ID: mdl-26391155
ABSTRACT

BACKGROUND:

Relationships between pharmacokinetic (PK) parameters of etoposide and toxicity survivals were reported in cancer patients treated at standard doses. The clinical impact of PK variations of etoposide high doses has never been explored in lymphoma patients. PATIENTS AND

METHODS:

The primary objective of LYMPK study was to prospectively assess the impact of etoposide PK parameters on outcomes in lymphoma patients receiving high-dose chemotherapy regimen (carmustine, cytarabine, etoposide and melphalan) followed by autologous stem cell transplant (ASCT). Individual etoposide PK parameters were estimated with a previously reported bi-compartment model using NONMEM(®) program. The impact of PK parameters on toxicity and survival was assessed using univariate/multivariate analyses.

RESULTS:

A total of 91 patients with malignant lymphoma [non-Hodgkin's lymphoma (NHL) 79; Hodgkin's lymphoma 12] at first line (n = 49) or relapse (n = 42) were enrolled in five centers. Large inter-individual variabilities in individual PK values were found for the same administration doses. In NHL patients, cumulative higher trough concentrations over the eight administrations of the first cycle (TotC min, categorized by the median 58.71 mg/L) had significant prognostic value regarding the 5-year progression-free survival (PFS 73.6 vs 46.5 %, P = 0.015) and 5-year overall survival (OS 74.0 vs 52.2 %, P = 0.034). Using a Cox model analysis, integrating disease settings (first line vs recurrent disease), simplified IPI and other prognostic factors, TotC min was the only significant independent prognostic factor influencing PFS, disease-specific survival and OS.

CONCLUSION:

This prospective study suggests survival of NHL patients treated with BEAM regimen and ASCT might be improved by increasing etoposide administration dose, or plasma concentration-based adjustment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco de Sangue Periférico / Etoposídeo Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica / Transplante de Células-Tronco de Sangue Periférico / Etoposídeo Idioma: En Ano de publicação: 2015 Tipo de documento: Article